Zafgen says obesity drug succeeds in late-stage study
Zafgen Inc said its experimental obesity drug, on complete clinical hold since last month after the death of two patients, met its main goals in a late-stage study in patients with a rare genetic eating disorder.
Wednesday, January 20, 2016
Why $ZFGN is UP 42% #BeforeBell @ $7.99 ?
Subscribe to:
Post Comments (Atom)
Powered By
Find Out MORE
No comments:
Post a Comment